The economics of febrile neutropenia: implications for the use of colony-stimulating factors
- 1 November 1998
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 34 (12), 1857-1864
- https://doi.org/10.1016/s0959-8049(98)00222-6
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile NeutropeniaNew England Journal of Medicine, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantationEuropean Journal Of Cancer, 1996
- Improving Treatment of Chemotherapy-Induced Neutropenic Fever by Administration of Colony-Stimulating FactorsJNCI Journal of the National Cancer Institute, 1995
- The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myelomaEuropean Journal Of Cancer, 1994
- Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer ChemotherapyJNCI Journal of the National Cancer Institute, 1993
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal Of Cancer, 1993
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumNew England Journal of Medicine, 1988
- A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and NeutropeniaNew England Journal of Medicine, 1986